|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Talbot R and Kirkham S: Colorectal cancer.
Lancet. 376:330author reply 331–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim SY, Choi EJ, Yun JA, Jung ES, Oh ST,
Kim JG, Kang WK and Lee SH: Syndecan-1 expression is associated
with tumor size and EGFR expression in colorectal carcinoma: A
clinicopathological study of 230 cases. Int J Med Sci. 12:92–99.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuo IM, Huang SF, Chiang JM, Yeh CY, Chan
KM, Chen JS and Yu MC: Clinical features and prognosis in
hepatectomy for colorectal cancer with centrally located liver
metastasis. World J Surg Oncol. 13:922015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Nordlinger B, Adam R, Köhne
CH, Pozzo C, Poston G, Ychou M and Rougier P: European Colorectal
Metastases Treatment Group: Towards a pan-European consensus on the
treatment of patients with colorectal liver metastases. Eur J
Cancer. 42:2212–2221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Díaz-Rubio E, Tabernero J, Gómez-España A,
Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina
JJ, et al: Phase III study of capecitabine plus oxaliplatin
compared with continuous-infusion fluorouracil plus oxaliplatin as
first-line therapy in metastatic colorectal cancer: Final report of
the Spanish Cooperative Group for the Treatment of Digestive Tumors
Trial. J Clin Oncol. 25:4224–4230. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cassidy J, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Randomized phase III study of capecitabine plus
oxaliplatin compared with fluorouracil/folinic acid plus
oxaliplatin as first-line therapy for metastatic colorectal cancer.
J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niitsu H, Hinoi T, Shimomura M, Egi H,
Hattori M, Ishizaki Y, Adachi T, Saito Y, Miguchi M, Sawada H, et
al: Up-front systemic chemotherapy is a feasible option compared to
primary tumor resection followed by chemotherapy for colorectal
cancer with unresectable synchronous metastases. World J Surg
Oncol. 13:1622015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tu J, Yu Y, Liu W and Chen S: Significance
of human epidermal growth factor receptor 2 expression in
colorectal cancer. Exp Ther Med. 9:17–24. 2015.PubMed/NCBI
|
|
12
|
Tol J, Koopman M, Cats A, Rodenburg CJ,
Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ,
Sinnige HA, et al: Chemotherapy, bevacizumab and cetuximab in
metastatic colorectal cancer. N Engl J Med. 360:563–572. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seki K, Tsuduki Y, Ioroi T, Yamane M,
Yamauchi H, Shiraishi Y, Ogawa T, Nakata I, Nishiguchi K,
Matsubayashi T, et al: Serum lactate dehydrogenase levels as a
predictive marker of oxaliplatin-induced hypersensitivity reactions
in Japanese patients with advanced colorectal cancer. Int J Med
Sci. 11:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Q, Zhang C, Guo J, Huang J, Xi X,
Zhang L and Cui X: Super-compact treatment with a high dose of
moxifloxacin in patients with drug-resistant tuberculosis and its
resistance mechanisms. Exp Ther Med. 9:1314–1318. 2015.PubMed/NCBI
|
|
15
|
Gan L, Lee I, Smith R, Argonza-Barrett R,
Lei H, McCuaig J, Moss P, Paeper B and Wang K: Sequencing and
expression analysis of the serine protease gene cluster located in
chromosome 19q13 region. Gene. 257:119–130. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nakamura T, Mitsui S, Okui A, Miki T and
Yamaguchi N: Molecular cloning and expression of a variant form of
hippostasin/KLK11 in prostate. Prostate. 54:299–305. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mavridis K and Scorilas A: Prognostic
value and biological role of the kallikrein-related peptidases in
human malignancies. Future Oncol. 6:269–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alexopoulou DK, Kontos CK, Christodoulou
S, Papadopoulos IN and Scorilas A: KLK11 mRNA expression predicts
poor disease-free and overall survival in colorectal adenocarcinoma
patients. Biomark Med. 8:671–685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patsis C, Yiotakis I and Scorilas A:
Diagnostic and prognostic significance of human kallikrein 11
(KLK11) mRNA expression levels in patients with laryngeal cancer.
Clin Biochem. 45:623–630. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Unal D, Tasdemir A, Oguz A, Eroglu C,
Cihan YB, Turak EE, Karaman H and Soyuer S: Is human kallikrein-11
in gastric cancer treated with surgery and adjuvant
chemoradiotherapy associated with survival? Pathol Res Pract.
209:779–783. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL,
Ye QH, Qin LX and Wu XZ: microRNA-29a suppresses cell proliferation
by targeting SPARC in hepatocellular carcinoma. Int J Mol Med.
30:1321–1326. 2012.PubMed/NCBI
|
|
23
|
Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT,
Liu B and Bao JK: Programmed cell death pathways in cancer: A
review of apoptosis, autophagy and programmed necrosis. Cell
Prolif. 45:487–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou F, Yang Y and Xing D: Bcl-2 and
Bcl-xL play important roles in the crosstalk between autophagy and
apoptosis. FEBS J. 278:403–413. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li S, Lu X, Chi P and Pan J:
Identification of HOXB8 and KLK11 expression levels as potential
biomarkers to predict the effects of FOLFOX4 chemotherapy. Future
Oncol. 9:727–736. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wen YG, Wang Q, Zhou CZ, Yan DW, Qiu GQ,
Yang C, Tang HM and Peng ZH: Identification and validation of
Kallikrein-ralated peptidase 11 as a novel prognostic marker of
gastric cancer based on immunohistochemistry. J Surg Oncol.
104:516–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pettersson F, Dalgleish AG, Bissonnette RP
and Colston KW: Retinoids cause apoptosis in pancreatic cancer
cells via activation of RAR-gamma and altered expression of
Bcl-2/Bax. Br J Cancer. 87:555–561. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan W, Xiaoyun H, Haifeng Q, Jing L,
Weixu H, Ruofan D, Jinjin Y and Zongji S: MicroRNA-218 enhances the
radiosensitivity of human cervical cancer via promoting radiation
induced apoptosis. Int J Med Sci. 11:691–696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
